<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890565</url>
  </required_header>
  <id_info>
    <org_study_id>392MD/39/C</org_study_id>
    <nct_id>NCT00890565</nct_id>
  </id_info>
  <brief_title>Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)</brief_title>
  <official_title>A Single-Blind, Randomized, Parallel Trial to Define the ECG Effects of Sancuso® (Granisetron Transdermal System) Compared to Placebo and Moxifloxacin in Healthy Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prostrakan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prostrakan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the electrocardiogram (ECG) effects of Sancuso® compared to
      placebo and moxifloxacin in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Granisetron is a well tested and established 5-HT3 receptor antagonist used in both oral and
      intravenous (IV) forms. A transdermal form of granisetron (Sancuso®) was approved by the
      United States (US) Food and Drug Administration (FDA) in September 2008.

      Many of the 5-HT3 antagonists were developed and approved before the adoption of the
      International Conference on Harmonisation (ICH) E14 standard on QTc and cardiac testing. The
      association of non-cardiac medicinal products with the potential to prolong the QT interval
      and induce torsades des pointes (TdP) has significant implications for the future development
      of medicinal products.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-matched, placebo-corrected change from baseline in QTc based on the Fridericia correction (QTcF).</measure>
    <time_frame>0 to 120 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTc with Bazett correction (QTcB), heart rate, PR interval, QRS interval, uncorrected QT interval, change in ECG morphological patterns and correlation between the QTcF change from baseline and plasma granisetron concentrations</measure>
    <time_frame>0 to 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of plasma concentration of granisetron versus QTcF, both graphical and mixed effects analyses of plasma concentration of granisetron versus QTcF will be performed</measure>
    <time_frame>0 to 120 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patch adhesion and residual granisetron after patch use.</measure>
    <time_frame>0 to 120 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A: Sancuso® patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Sancuso® patch (Day 1) and placebo IV (Day 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: IV Granisetron 10 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B: placebo patch (Day 1) and granisetron IV (Day 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Matching placebo patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment C: placebo patch (Day 1) and placebo IV (Day 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: Oral Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment D: placebo patch (Day 1) and oral moxifloxacin (Day 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>granisetron</intervention_name>
    <description>Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3</description>
    <arm_group_label>Treatment A: Sancuso® patch</arm_group_label>
    <arm_group_label>Treatment B: IV Granisetron 10 mcg/kg</arm_group_label>
    <arm_group_label>Treatment C: Matching placebo patch</arm_group_label>
    <arm_group_label>Treatment D: Oral Moxifloxacin 400 mg</arm_group_label>
    <other_name>Granisetron Transdermal System</other_name>
    <other_name>Sancuso® patch</other_name>
    <other_name>Kytril®</other_name>
    <other_name>Granisetron Injection</other_name>
    <other_name>IV Placebo (0.9% saline)</other_name>
    <other_name>Placebo patches</other_name>
    <other_name>Avelox® Oral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects

          -  Aged between 18 and 50 years, inclusive, at screening

          -  BMI between 18.0 and 32.0 kg/m², inclusive

        Exclusion Criteria:

          -  History of drug abuse

          -  Known hypersensitivity to granisetron, moxifloxacin, or related compounds, such as
             ciprofloxacin and levofloxacin

          -  Sustained supine systolic blood pressure &gt;140 mmHg or &lt;100 mmHg or a diastolic blood
             pressure &gt;95 mmHg at Screening or baseline

          -  Pulse rate at rest of &lt; 45 bpm or &gt; 100 bpm

          -  Abnormal Screening ECG indicating a second- or third degree AV block, or one or more
             of the following: QRS &gt;120 milliseconds (ms); QTcF &gt; 430 (males) or 450 (females) ms;
             PR interval &gt;240 ms; any rhythm, other than sinus rhythm, interpreted to be clinically
             significant by the Investigator

          -  Known history of long-QT syndrome, angina, myocardial ischemia or infarction,
             congestive heart failure, myocarditis, chest pain or dyspnea on exertion

          -  Electrolyte disturbances (such as uncorrected hypokalemia/hyperkalemia,
             hypomagnesemia, hypocalcemia, or hypophosphatemia), idiopathic cardiomyopathy,
             unexplained syncope, hypertrophic cardiomyopathy, or sudden unexplained death at a
             young age (&lt; 40 years) in a first-degree relative.

          -  Has used any medications or consumed any foods contraindicated in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bridget O'Mahony, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Prostrakan Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical Research, LLC</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>April 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2009</study_first_posted>
  <last_update_submitted>September 24, 2010</last_update_submitted>
  <last_update_submitted_qc>September 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Bridget O'Mahony/Clinical Research Manager</name_title>
    <organization>Strakan Pharmaceuticals Ltd</organization>
  </responsible_party>
  <keyword>Electrocardiogram</keyword>
  <keyword>Effect on electrocardiogram</keyword>
  <keyword>Granisetron</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Pharmacokinetic profile</keyword>
  <keyword>Sancuso® patch</keyword>
  <keyword>Transdermal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

